Serenex

The company's core business revolved around its proprietary drug discovery platform, which facilitated high-throughput screening of small molecules against various therapeutic and toxicity targets. This technology was designed to identify biologically active compounds and their physiological targets simultaneously, streamlining the drug discovery process. Serenex developed a library of small molecule Hsp90 inhibitors, with applications not only in cancer but also potentially in inflammatory and neurodegenerative diseases. Its primary clients were in the pharmaceutical sector through partnership and licensing deals. The company's lead product candidate, SNX-5422, was an oral Hsp90 inhibitor that entered Phase I clinical trials for treating solid tumors and hematological malignancies.

Financially, Serenex was venture-backed, securing a total of $79 million over four funding rounds between 2002 and 2007. Its investors included notable firms such as Lilly Ventures, Takeda Ventures, and Intersouth Partners. The company's significant progress and promising pipeline culminated in its acquisition by Pfizer in March 2008, a move that expanded Pfizer's oncology portfolio. At the time of the acquisition, Serenex was based in Durham, North Carolina.